CHI Announces Challenges of Targeting Cancer Stem Cells at Cancer Biologics 2012

Join us for a roundtable discussion during the Cancer Biologics Conference at the Tri-Conference. Discussion moderated by: Norman J. Maitland, Ph.D., Chief Scientific Officer, Procure Therapeutics Ltd.
 
 
Spread the Word
Listed Under

Tags:
* Event
* San Francisco
* Drug Discovery
* Drug Development
* Pharmaceutical
* Biotech

Industrys:
* Biotech
* Health
* Science

Location:
* Needham - Massachusetts - US

Feb. 7, 2012 - PRLog -- NEEDHAM, MASS. – Cambridge Healthtech Institute announces The Challenges of Targeting Cancer Stem Cells .  This roundtable discussion will be held during  during the Cancer Biologics Conference at the Tri-Conference.

Featuring over 25 presentations, this unique three-day conference presents advances in antibody drug conjugates, multi-specifics, drug combinations, enhanced targeting and PKPD, translational studies and immunotherapy, is being held at the Molecular Med TRI-CON 2012 on Feb. 21-23 at the Moscone in San Francisco.

Moderated by: Norman J. Maitland, Ph.D., Chief Scientific Officer, Procure Therapeutics Ltd . Join leading cancer research experts to discuss:

- How cancer stem cells differ from normal stem cells and other cancer cells
- Approaches to the identification and evaluation of new cancer stem cell targets
- Payloads that overcome the enhanced resistance of cancer stem cells
- Issues to do with selection of animal model
- Concerns to do with delivery and clearance
- Potential safety issues
- Strategy for entering clinical trials
- Demonstration clinical benefit

For more information and to view the full agenda visit, http://www.triconference.com/Cancer-Biologics/

The Cancer Biologics conference is one of the program offerings at CHI’s flagship event, the Molecular Medicine Tri-Conference (February 19-23).  This international event features 2 partnering forums, 5 symposia, 18 short courses, and 12 core programs around 4 scientific channels: diagnostics, drug discovery & development, informatics, and cancer. Over 3000 attendees and 150+ sponsors & exhibitors will gather in shared networking functions and in the exhibit/poster hall.

To view the entire conference agenda and to register, please visit http://www.triconference.com/Cancer-Biologics/

Writers and editors are encouraged to attend. To request a press pass, contact Tracey Fielding at tfielding@healthtech.com.

About Cambridge Healthtech Institute (www.chicorporate.com)

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

# # #

Since 1992, Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations.
End
Source:
Email:***@healthtech.com Email Verified
Phone:781.972.5400
Zip:02494
Tags:Event, San Francisco, Drug Discovery, Drug Development, Pharmaceutical, Biotech
Industry:Biotech, Health, Science
Location:Needham - Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share